Gurpreet Sidhu, MD
Interventional Cardiology · Chester, NJNPI 1255641163
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Cardiovascular Systems Inc. at 43.6% of the total. Reporting peaked in 2019 at $4,076 and has fallen 65.4% since, to $1,411 in 2025.
Across 445 payments — averaging $36.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$7K
- Abbott$4K
- Medtronic$868
- Amgen$773
- Boston Scientific$529
- Novartis$439
- plus $2K from 28 others
What the payments were for
- Food & beverage$16,086100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 107 | $7,018 |
| Abbott | 84 | $3,986 |
| Medtronic(2 entities) | 22 | $868 |
| Amgen | 45 | $773 |
| Boston Scientific | 10 | $529 |
| Novartis | 37 | $439 |
| AstraZeneca | 21 | $404 |
| Johnson & Johnson | 34 | $358 |
| Merck | 11 | $184 |
| Chiesi USA, Inc. | 6 | $166 |
| Pfizer | 11 | $164 |
| Atricure, Inc. | 2 | $161 |
| Sanofi-aventis U.S. LLC | 7 | $115 |
| Amarin Pharma, Inc. | 8 | $115 |
| Stryker | 1 | $110 |
| E.r. Squibb & Sons, L.L.C. | 7 | $103 |
| Arbor Pharmaceuticals, Inc. | 5 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $62 |
| Bayer | 2 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $48 |
| Abiomed | 2 | $45 |
| Esperion Therapeutics, Inc. | 3 | $44 |
| Shockwave Medical, Inc | 1 | $44 |
| Biosense Webster, Inc. | 1 | $38 |
| Novo Nordisk | 2 | $35 |
| Penumbra, Inc. | 2 | $33 |
| Althera Pharmaceuticals LLC | 2 | $32 |
| Cvrx, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Cardinal Health 200 LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Diamondback Coronary$2,509
- Coronary Orbital Atherectomy System$1,510
- DRAGONFLY OPSTAR$632
- Diamondback Peripheral$579
- Xience Sierra Coronary Stent System$404
- Peripheral Orbital Atherectomy System$398
- Optis Coronary Imaging System$290
- XIENCE SKYPOINT$246
- SYNERGY$221
- ATRICURE SYNERGY ABLATION SYSTEM$147
- CoreValve Evolut$144
- GENERAL - STENTS$127
- FARXIGA$125
- Repatha$122
- ONYX FRONTIER$114
- FlowTriever$110
How this compares
$16,100 in reported general payments places this provider in the 70th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $172,937 |
| EntrestoSacubitril/Valsartan | 45 | $74,488 |
| XareltoRivaroxaban | 67 | $71,286 |
| Repatha SureclickEvolocumab | 70 | $66,783 |
| OzempicSemaglutide | 42 | $66,474 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 58 | $37,101 |
| FarxigaDapagliflozin Propanediol | 26 | $36,367 |
| JardianceEmpagliflozin | 19 | $30,177 |
| Praluent PenAlirocumab | 13 | $15,918 |
| BrilintaTicagrelor | 13 | $14,610 |
| WegovySemaglutide | 11 | $14,110 |
| MounjaroTirzepatide | 13 | $13,698 |
| EdarbiAzilsartan Medoxomil | 15 | $10,388 |
| BenicarOlmesartan Medoxomil | 12 | $6,873 |
| Nebivolol Hcl | 61 | $5,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $172,937134 claims |
| Novo NordiskOzempic, Wegovy | $35 | $80,58553 claims |
| NovartisEntresto | $439 | $74,48845 claims |
| Johnson & JohnsonXarelto | $358 | $71,28667 claims |
| AstraZenecaFarxiga, Brilinta | $404 | $50,97639 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $68 | $47,48973 claims |
| Boehringer IngelheimJardiance | $16 | $30,17719 claims |
| AbbVieSynthroid | $15 | $96726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Chester
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
- Kintur SanghviBordentown$139K
- Dimitrios KarmpaliotisMorristown$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.